Business
CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten)
NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed®, an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ (aficamten), indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.1 “MYQORZO represents a meaningful advancement for adults living with obstructive hypertrophic cardiomyopathy, and we are extremely excited to partner closely with the team
About this update from Cytokinetics, Incorporated
[{"type":"image","alt":"CareMed Specialty Pharmacy","displaySize":"","headline":null,"caption":"CareMed Specialty Pharmacy","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/c0f83fef06df8cb8f849931bbccd532e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EkjmtlKOxV6Fy2Pmi0LBgg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0f83fef06df8cb8f849931bbccd532e","width":300,"height":83}},"lazy":false},{"type":"text","content":"NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed®, an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ (aficamten), indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.1","length":334,"tagName":"p"},{"type":"text","content":"“MYQORZO represents a meaningful advancement for adults living with obstructive hypertrophic cardiomyopathy, and we are extremely excited to partner closely with the team at Cytokinetics to support patients and caregivers throughout their treatment journey,” said Benito Fernandez, Chief Commercial Officer. “CareMed’s partnership with Cytokinetics reinforces our leading specialty pharmacy platform’s strength and ability to support patients and caregivers suffering from rare and complex disease states.”","length":506,"tagName":"p"},{"type":"text","content":"MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with HCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset of action and reversibility.2","length":330,"tagName":"p"},{"type":"text","content":"The approval is based on the positive results from the pivotal Phase 3 clinical trial, SEQUOIA-HCM, published in the New England Journal of Medicine, which demonstrated robust efficacy, safety, and clinically meaningful benefits across symptoms, exercise capacity, hemodynamics, and biomarker endpoints. The results from SEQUOIA-HCM showed that treatment with MYQORZO for 24 weeks significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake (pVO2) measured b...